PURPOSE: Technical studies suggest that computed tomography (CT) -based simulation improves the therapeutic ratio for thoracic radiation therapy (TRT), although few studies have evaluated its use or impact on outcomes. METHODS: We used the Surveillance, Epidemiology and End Results (SEER) -Medicare linked data to identify CT-based simulation for TRT among Medicare beneficiaries diagnosed with stage III non-small-cell lung cancer (NSCLC) between 2000 and 2005. Demographic and clinical factors associated with use of CT simulation were identified, and the impact of CT simulation on survival was analyzed by using Cox models and propensity score analysis. RESULTS: The proportion of patients treated with TRT who had CT simulation increased from 2.4% in 1994 to 34.0% in 2000 to 77.6% in 2005. Of the 5,540 patients treated with TRT from 2000 to 2005, 60.1% had CT simulation. Geographic variation was seen in rates of CT simulation, with lower rates in rural areas and in the South and West compared with those in the Northeast and Midwest. Patients treated with chemotherapy were more likely to have CT simulation (65.2% v 51.2%; adjusted odds ratio, 1.67; 95% CI, 1.48 to 1.88; P < .01), although there was no significant association between use of surgery and CT simulation. Controlling for demographic and clinical characteristics, CT simulation was associated with lower risk of death (adjusted hazard ratio, 0.77; 95% CI, 0.73 to 0.82; P < .01) compared with conventional simulation. CONCLUSION: CT-based simulation has been widely, although not uniformly, adopted for the treatment of stage III NSCLC and is associated with higher survival among patients receiving TRT.
PURPOSE: Technical studies suggest that computed tomography (CT) -based simulation improves the therapeutic ratio for thoracic radiation therapy (TRT), although few studies have evaluated its use or impact on outcomes. METHODS: We used the Surveillance, Epidemiology and End Results (SEER) -Medicare linked data to identify CT-based simulation for TRT among Medicare beneficiaries diagnosed with stage III non-small-cell lung cancer (NSCLC) between 2000 and 2005. Demographic and clinical factors associated with use of CT simulation were identified, and the impact of CT simulation on survival was analyzed by using Cox models and propensity score analysis. RESULTS: The proportion of patients treated with TRT who had CT simulation increased from 2.4% in 1994 to 34.0% in 2000 to 77.6% in 2005. Of the 5,540 patients treated with TRT from 2000 to 2005, 60.1% had CT simulation. Geographic variation was seen in rates of CT simulation, with lower rates in rural areas and in the South and West compared with those in the Northeast and Midwest. Patients treated with chemotherapy were more likely to have CT simulation (65.2% v 51.2%; adjusted odds ratio, 1.67; 95% CI, 1.48 to 1.88; P < .01), although there was no significant association between use of surgery and CT simulation. Controlling for demographic and clinical characteristics, CT simulation was associated with lower risk of death (adjusted hazard ratio, 0.77; 95% CI, 0.73 to 0.82; P < .01) compared with conventional simulation. CONCLUSION: CT-based simulation has been widely, although not uniformly, adopted for the treatment of stage III NSCLC and is associated with higher survival among patients receiving TRT.
Authors: B Ashleigh Guadagnolo; Kai-Ping Liao; Sharon H Giordano; Linda S Elting; Thomas A Buchholz; Ya-Chen Tina Shih Journal: J Oncol Pract Date: 2014-04-22 Impact factor: 3.840
Authors: Shervin M Shirvani; Jing Jiang; Daniel R Gomez; Joe Y Chang; Thomas A Buchholz; Benjamin D Smith Journal: Lung Cancer Date: 2013-08-21 Impact factor: 5.705
Authors: Yaacov Richard Lawrence; Rebecca Paulus; Corey Langer; Maria Werner-Wasik; Mark K Buyyounouski; Ritsuko Komaki; Mitchell Machtay; Colum Smith; Rita S Axelrod; Todd Wasserman; Jeffrey D Bradley; Benjamin Movsas Journal: Lung Cancer Date: 2013-03-07 Impact factor: 5.705
Authors: Steven H Lin; Thomas J George; Edgar Ben-Josef; Jeffrey Bradley; Kevin S Choe; Martin J Edelman; Chandan Guha; Sunil Krishnan; Theodore S Lawrence; Quynh-Thu Le; Bo Lu; Minesh Mehta; David Peereboom; Jann Sarkaria; Jinsil Seong; Dian Wang; Meng X Welliver; C Norman Coleman; Bhadrasain Vikram; Stephen Yoo; Christine H Chung Journal: J Natl Cancer Inst Date: 2013-03-15 Impact factor: 13.506
Authors: Nirav S Kapadia; Luca F Valle; Julie A George; Reshma Jagsi; Thomas A D'Amico; Elisabeth U Dexter; Fawn D Vigneau; Feng Ming Kong Journal: Ann Thorac Surg Date: 2017-10-26 Impact factor: 4.330
Authors: Reshma Jagsi; Justin E Bekelman; Aileen Chen; Ronald C Chen; Karen Hoffman; Ya-Chen Tina Shih; Benjamin D Smith; James B Yu Journal: Int J Radiat Oncol Biol Phys Date: 2014-09-01 Impact factor: 7.038